Mergers and Acquisitions Overview - 89bio, Inc. will be acquired by Roche for $14.50 per share in cash, plus a contingent value right of up to $6.00 per share, with investigations into the Board's fiduciary duties regarding fair process and value [2] - Barinthus Biotherapeutics plc will merge with Clywedog Therapeutics, with Barinthus shareholders receiving one share of the new company for each ADS or ordinary share owned, and Clywedog shareholders receiving 4.358932 shares, raising questions about the Board's fiduciary duties [4] - Dayforce, Inc. is set to be acquired by Thoma Bravo for $70.00 per share in cash, with an enterprise value of $12.3 billion, while investigations focus on whether the deal consideration is fair compared to the 52-week high of $82.69 [6] - Verint Systems Inc. will also be acquired by Thoma Bravo for $20.50 per share, with investigations into the Board's fiduciary duties and the deal's fairness compared to the 52-week high of $34.80 [8]

Core Viewpoint - Halper Sadeh LLC is investigating the fairness of the merger between Axcelis Technologies, Inc. and Veeco Instruments Inc. for Axcelis shareholders, who are expected to own approximately 58% of the combined company upon closing [1]. Group 1: Investigation Details - The investigation focuses on whether Axcelis and its board violated federal securities laws or breached fiduciary duties by not obtaining the best possible consideration for shareholders and failing to disclose all material information necessary for assessing the merger [3]. - Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures, and other relief related to the proposed transaction [4]. Group 2: Legal Rights and Options - Axcelis shareholders are encouraged to learn more about their legal rights and options regarding the merger [2].

Core Insights - Several healthcare and biotech stocks experienced significant price movements on September 29, driven by clinical trial updates, regulatory progress, and strategic announcements Company Performance Highlights - Phio Pharmaceuticals Corp. (PHIO) saw an 8.9% increase in after-hours trading, rising from $2.36 to $2.57, following a 5.83% gain during the regular session, attributed to a positive safety committee recommendation for its PH-762 skin cancer trial [1][2] - Barinthus Biotherapeutics plc (BRNS) rose 8.11% in after-hours trading to $1.60 after closing at $1.48, with a notable 21.3% gain, driven by renewed interest in its immunotherapeutic pipeline [2][3] - Neogen Corp. (NEOG) jumped 5.59% in after-hours trading to $5.90, reversing a 1.41% decline earlier in the day, following announcements of its upcoming earnings release and a renewed sponsorship agreement [3][4] - OKYO Pharma Ltd. (OKYO) increased by 9% in after-hours trading to $2.18 after a decline of 8.26% during the regular session, due to renewed focus on its clinical-stage program for urcosimod [5] - Aurinia Pharmaceuticals Inc. (AUPH) rose 8.05% in after-hours trading to $11.95, despite a 15.83% drop earlier, reflecting heightened activity around its lupus nephritis treatment, LUPKYNIS, and a collaboration with Otsuka Pharmaceutical [6] - RAPT Therapeutics, Inc. (RAPT) climbed 4.43% in after-hours trading to $27.80, following the FDA's clearance of its IND application for RPT904, allowing it to proceed with a Phase 2b trial targeting food allergies [7][8]

Market Overview - U.S. stocks showed mixed trading with the Nasdaq down approximately 0.1% on Wednesday [1] - The Dow Jones increased by 0.08% to 44,060.17, while the S&P 500 rose by 0.03% to 6,245.49 [1] Sector Performance - Health care shares experienced a rise of 1.2% on Wednesday [1] - Energy stocks saw a decline of 0.8% [1] Company Earnings - Bank of America Corp reported second-quarter fiscal 2025 net income of $7.1 billion, up from $6.9 billion a year ago, with EPS of $0.89, surpassing the analyst consensus estimate of $0.87 [2] - Revenue for Bank of America increased by 4% year-over-year to $26.5 billion, although it fell short of the analyst consensus estimate of $26.8 billion [2] Commodity Prices - Oil prices decreased by 1.1% to $65.81, while gold prices increased by 0.3% to $3,347.00 [4] - Silver prices fell by 0.2% to $38.035, and copper prices dropped by 1.6% to $5.49 [4] Asian Market Performance - Asian markets closed mixed, with Japan's Nikkei down 0.04% and Hong Kong's Hang Seng down 0.29% [6] - China's Shanghai Composite also fell by 0.04%, while India's BSE Sensex gained 0.08% [6] Notable Stock Movements - Aptorum Group Limited shares surged by 254% to $3.4413 following an all-stock merger agreement with DiamiR [8] - Nuwellis, Inc. shares increased by 140% to $16.58 after securing a U.S. patent for a blood filtering machine [8] - Barinthus Biotherapeutics plc shares rose by 92% to $1.96 [8] - Soluna Holdings, Inc. shares dropped by 33% to $0.5083 after announcing a $5 million public offering [8] - Cyclacel Pharmaceuticals, Inc. shares fell by 25% to $9.20, and Onconetix, Inc. shares decreased by 22% to $3.5150 following a merger announcement [8] Economic Indicators - U.S. crude oil inventories declined by 3.859 million barrels for the week ended July 11 [9] - U.S. industrial production increased by 0.3% in June, exceeding market estimates of a 0.1% rise [9] - U.S. producer prices remained unchanged in June compared to May, contrasting with a revised 0.3% gain in the previous period [10]